{
  "pmid": "35266952",
  "uid": "35266952",
  "title": "Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.",
  "abstract": "",
  "authors": [
    {
      "last_name": "Tannock",
      "fore_name": "Ian F",
      "initials": "IF",
      "name": "Ian F Tannock",
      "affiliations": [
        "Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada."
      ]
    },
    {
      "last_name": "Pond",
      "fore_name": "Gregory R",
      "initials": "GR",
      "name": "Gregory R Pond",
      "affiliations": [
        "Department of Oncology, McMaster University, Hamilton, Ontario, Canada."
      ]
    },
    {
      "last_name": "Booth",
      "fore_name": "Christopher M",
      "initials": "CM",
      "name": "Christopher M Booth",
      "affiliations": [
        "Division of Cancer Care and Epidemiology, Departments of Oncology and Public Health Sciences, Queen's University, Kingston, Ontario, Canada."
      ]
    }
  ],
  "journal": {
    "title": "JAMA oncology",
    "iso_abbreviation": "JAMA Oncol",
    "issn": "2374-2445",
    "issn_type": "Electronic",
    "volume": "8",
    "issue": "5",
    "pub_year": "2022",
    "pub_month": "May",
    "pub_day": "01"
  },
  "start_page": "679",
  "end_page": "680",
  "pages": "679-680",
  "language": "eng",
  "publication_types": [
    "Journal Article"
  ],
  "keywords": [
    "Antineoplastic Agents",
    "Disease-Free Survival",
    "Humans",
    "Neoplasms",
    "Progression-Free Survival"
  ],
  "article_ids": {
    "pubmed": "35266952",
    "doi": "10.1001/jamaoncol.2021.8206",
    "pii": "2790095"
  },
  "doi": "10.1001/jamaoncol.2021.8206",
  "dates": {
    "completed": "2022-05-23",
    "revised": "2022-06-08"
  },
  "chemicals": [
    "Antineoplastic Agents"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "current_affiliation",
    "retrieved_date": "2025-07-30T14:52:52.295582",
    "pmid": "35266952"
  }
}